Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
MWN-AI** Summary
Arch Biopartners Inc. has announced a significant advancement in its clinical research efforts, having secured a Clinical Trial Agreement (CTA) with the Fraser Health Authority for its Phase II trial of LSALT peptide, aimed at preventing cardiac surgery-associated acute kidney injury (CS-AKI). This partnership will enable the Royal Columbian Hospital (RCH) to move forward with preparations for patient recruitment, marking RCH as the ninth globally activated site and the fourth in Canada for this trial.
The completion of the Clinical Trial Application means RCH has obtained essential Research Ethics Board approvals, paving the way for patient recruitment. Other participating Canadian sites include notable institutions like Toronto General Hospital, St. Michael’s Hospital, and the University of Calgary, which are all actively enrolling patients. Arch is also in discussions with other leading cardiac surgery centers in North America to broaden the trial's reach.
Arch Biopartners focuses on developing novel therapeutics for acute kidney injury (AKI) and chronic kidney disease (CKD). Its lead asset, LSALT peptide, is designed to address CS-AKI, while other initiatives like the repurposed drug cilastatin target toxin-induced AKI. Together, these programs represent innovative approaches tackling serious kidney health challenges for over 800 million individuals worldwide.
With a commitment to advancing its pipeline, Arch Biopartners aims to meet pressing healthcare needs and develop new treatments for kidney conditions. This announcement signifies a crucial step in its clinical journey, bolstering efforts to enhance kidney health and potentially transform treatment options in the field. Stakeholders and investors are encouraged to follow the company’s updates, which can be found on its official website and social media platforms.
MWN-AI** Analysis
Arch Biopartners Inc. (TSX Venture: ARCH; OTCQB: ACHFF) has made significant strides with its recent Clinical Trial Agreement (CTA) with the Fraser Health Authority, initiating the Phase II trial evaluating the LSALT peptide for cardiac surgery-associated acute kidney injury (CS-AKI). This development is crucial for the company as it expands its clinical footprint, now having nine global sites and four in Canada actively recruiting patients.
Investors should note the larger context of Arch's pipeline, which includes two other promising candidates—Cilastatin and a CKD platform—each targeting significant unmet medical needs in kidney care. The global prevalence of kidney ailments, documented to affect over 800 million people, underlines a massive market potential for these therapies. The successful completion of these Phase II trials can significantly enhance Arch’s prospects, as positive results could lead to lucrative licensing agreements or partnerships with larger pharmaceutical companies.
Moreover, the achievement of necessary regulatory and ethical approvals reaffirms the credibility and operational capability of Arch. This progress can positively influence investor sentiment and stock performance. However, investors should remain aware of the inherent risks typical in biotech investments, especially concerning clinical trial outcomes and the ability to secure further financing for ongoing developments.
Arch's healthy cash position and ongoing discussions with additional trial sites in North America also position it to leverage future growth opportunities. While the stock may be subject to volatility based on trial data releases and broader market movements, the long-term potential in the kidney health space suggests that Arch Biopartners could yield favorable returns for investors willing to navigate its short-term fluctuations. Overall, while maintaining caution, considering a position in Arch could be strategically beneficial as the company continues to advance its innovative therapies.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TORONTO, March 24, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Authority has entered into a Clinical Trial Agreement (“CTA”) with Arch to enable the Royal Columbian Hospital (RCH) to begin preparing for the recruitment phase in Arch’s ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
With the Clinical Trial Application (CTA) completed, RCH has now received final Research Ethics Board and operational approvals, including the final letter of authorization from Fraser Health. RCH will be the ninth site activated globally in the study and will be the fourth site to recruit patients in Canada.
Toronto General Hospital, part of University Health Network, St. Michael’s Hospital, part of Unity Health Toronto, and the University of Calgary, Cumming School of Medicine, continue to actively enroll new patients into the trial.
The Company is currently progressing feasibility and start-up discussions with additional leading cardiac surgery centres in Canada and the United States.
About Arch Biopartners
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The Company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury.
Arch’s development pipeline includes:
- LSALT peptide: in a Phase II trial targeting cardiac surgery-associated AKI.
- Cilastatin: a repurposed drug in a Phase II trial targeting toxin-induced AKI.
- CKD Platform: next-generation therapeutics targeting chronic kidney disease.
These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million people worldwide1. Both lead programs are currently enrolling patients at Canadian clinical sites, with additional North American sites in development.
For more details about the Company’s science and ongoing clinical trials, please visit: www.archbiopartners.com/our-science
Follow Arch on LinkedIn, Bluesky, and X (formerly Twitter) for scientific insights and industry news.
The Company has 66,933,289 common shares outstanding.
For more information, please contact:
| Aaron Benson Director of Communications Arch Biopartners, Inc. 647-428-7031 | |
Send a message or subscribe for trial updates and company news at www.archbiopartners.com/contact-us
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of the Company’s future performance, liquidity, and capital resources, as well as the ongoing development of its drug candidates targeting chronic kidney disease and the dipeptidase-1 (DPEP-1) pathway, including the outcome of its clinical trials relating to LSALT peptide (Metablok) or cilastatin, the successful commercialization and marketing of its drug candidates, whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe, and other countries, its ability to raise capital to fund its business plans, the efficacy of its drug candidates compared to the drug candidates developed by competitors, its ability to retain and attract key management personnel, and the breadth of, and its ability to protect, its intellectual property portfolio. These statements are based on management’s current expectations and beliefs, including certain factors and assumptions, as described in the Company’s most recent annual audited financial statements and related management discussion and analysis under the heading “Business Risks and Uncertainties”. As a result of these risks and uncertainties, or other unknown risks and uncertainties, the actual results may differ materially from those contained in any forward-looking statements. The words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company undertakes no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including the Company’s most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (“SEDAR”) website at www.sedarplus.ca.
References:
- Mark, Patrick B et al. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet, 2025;406(10518), 2461 - 2482. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01853-7/fulltext
The scientific and medical content of this release has been reviewed and approved by the Company’s Chief Science Officer.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FAQ**
What specific outcomes does Arch Biopartners Inc (ACHFF) expect from the Phase II trial of LSALT peptide in preventing cardiac surgery-associated acute kidney injury, and how will these results impact their development pipeline?
How does Arch Biopartners Inc (ACHFF) plan to address potential risks mentioned in their forward-looking statements, especially regarding the efficacy of their drug candidates in comparison to competitors?
Given that LSALT peptide is currently undergoing trials across several Canadian sites, how is Arch Biopartners Inc (ACHFF) ensuring patient recruitment and engagement at each of these locations?
What strategies is Arch Biopartners Inc (ACHFF) employing to secure additional funding for its ongoing clinical trials, particularly in light of the high unmet needs in kidney care?
**MWN-AI FAQ is based on asking OpenAI questions about Arch Biopartners Inc. (TSXVC: ARCH:CC).
NASDAQ: ARCH:CC
ARCH:CC Trading
1.28% G/L:
$3.95 Last:
23,777 Volume:
$3.98 Open:
